Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone215-333-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$684.56 million
Profitability
Miscellaneous
Employees1,251
Next Earnings Date8/27/2019 (Estimated)
OptionableOptionable
Lannett (NYSE:LCI) Frequently Asked Questions
What is Lannett's stock symbol?
Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."
How were Lannett's earnings last quarter?
Lannett Company, Inc. (NYSE:LCI) released its earnings results on Tuesday, August, 28th. The company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The business had revenue of $170.90 million for the quarter, compared to the consensus estimate of $171.21 million. Lannett had a positive return on equity of 25.79% and a negative net margin of 39.84%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.40 earnings per share. View Lannett's Earnings History.
When is Lannett's next earnings date?
What price target have analysts set for LCI?
2 equities research analysts have issued twelve-month price targets for Lannett's stock. Their predictions range from $9.00 to $9.00. On average, they anticipate Lannett's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price. View Analyst Price Targets for Lannett.
What is the consensus analysts' recommendation for Lannett?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lannett.
Has Lannett been receiving favorable news coverage?
Media coverage about LCI stock has trended positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lannett earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Lannett.
Are investors shorting Lannett?
Lannett saw a decline in short interest in July. As of July 31st, there was short interest totalling 16,909,700 shares, a decline of 17.8% from the June 30th total of 20,576,700 shares. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is presently 14.0 days. Approximately 60.8% of the shares of the stock are sold short. View Lannett's Current Options Chain.
Who are some of Lannett's key competitors?
Some companies that are related to Lannett include Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), Zymeworks (ZYME), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Omeros (OMER), Y-mAbs Therapeutics (YMAB), Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Axsome Therapeutics (AXSM), ANI Pharmaceuticals (ANIP) and ZIOPHARM Oncology (ZIOP).
What other stocks do shareholders of Lannett own?
Who are Lannett's key executives?
Lannett's management team includes the folowing people:
- Mr. Timothy C. Crew, CEO & Director (Age 58)
- Mr. Martin P. Galvan, VP of Fin. & CFO (Age 67)
- Mr. Samuel H. Israel, Gen. Counsel & Chief Legal Officer (Age 57)
- Mr. John M. Abt, VP & Chief Quality Operations Officer (Age 54)
- Mr. John Kozlowski, Chief of Staff & Strategy Officer (Age 47)
Who are Lannett's major shareholders?
Lannett's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.77%), D. E. Shaw & Co. Inc. (8.78%), Vanguard Group Inc. (6.84%), JPMorgan Chase & Co. (5.46%), LSV Asset Management (5.25%) and Morgan Stanley (2.19%). Company insiders that own Lannett stock include Albert Paonessa III, Arthur P Bedrosian, David Farber, Jeffrey Farber, Kevin Smith, Patrick G Lepore and Timothy C Crew. View Institutional Ownership Trends for Lannett.
Which institutional investors are selling Lannett stock?
LCI stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, JPMorgan Chase & Co., Canada Pension Plan Investment Board, A.R.T. Advisors LLC, Alambic Investment Management L.P., Municipal Employees Retirement System of Michigan, Invesco Ltd. and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Lannett.
Which institutional investors are buying Lannett stock?
LCI stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., D. E. Shaw & Co. Inc., Marshall Wace LLP, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc., Jacobs Levy Equity Management Inc., Morgan Stanley and Strs Ohio. Company insiders that have bought Lannett stock in the last two years include Albert Paonessa III, Jeffrey Farber, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett.
How do I buy shares of Lannett?
Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lannett's stock price today?
One share of LCI stock can currently be purchased for approximately $7.05.
How big of a company is Lannett?
Lannett has a market capitalization of $277.21 million and generates $684.56 million in revenue each year. The company earns $28.69 million in net income (profit) each year or $3.10 on an earnings per share basis. Lannett employs 1,251 workers across the globe.View Additional Information About Lannett.
What is Lannett's official website?
How can I contact Lannett?
Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at 215-333-9000.
MarketBeat Community Rating for Lannett (NYSE LCI)
MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
